AREC ARECOR THERAPEUTICS PLC

EQS-News: Arecor Therapeutics scientist hopeful that artificial pancreas 'edging closer'

EQS-News: Arecor Therapeutics PLC
Arecor Therapeutics scientist hopeful that artificial pancreas 'edging closer'

15.11.2022 / 13:43 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct

15.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Arecor Therapeutics PLC
United States
ISIN: GB00BMWLM973
EQS News ID: 1488157

 
End of News EQS News Service

1488157  15.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1488157&application_name=news&site_id=research_pool
EN
15/11/2022

Underlying

ARECARECOR THERAPEUTICS PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ARECOR THERAPEUTICS PLC

 PRESS RELEASE
Free
AREC ARECOR THERAPEU...

Arecor announces Co-development Agreement with US Insulin Pump Device ...

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292 This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").   Arecor Therapeutics plc(“Arecor” or the “Company”) Co-development Agreement with US Insulin Pump Device Company for AT278 andSale of Royalty and Technology Access Fees for up to $11 million AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in developm...

September 25, 2025 1 EN
 PRESS RELEASE
Free
AREC ARECOR THERAPEU...

Arecor and Medtronic Diabetes establish collaboration to develop a nov...

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump Cambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing...

May 9, 2024 1 EN
 PRESS RELEASE
Free
AREC ARECOR THERAPEU...

ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP...

ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) product with enhanced bioavailability Collaboration focused on overcoming the challenges of oral peptide delivery using a novel lipid technology to provide a more convenient treatment option for patients with diabete...

March 12, 2024 1 EN
 PRESS RELEASE
Free
AREC ARECOR THERAPEU...

First Product Incorporating Arecor’s Arestat Technology, At220, Launch...

First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe Arecor Therapeutics plc(“Arecor” or the “Group”) FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE First commercial sale triggers milestone payment and future royalties to Arecor Cambridge, UK, 17 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces the triggering of a milestone payment from its global pharmaceutical partner, following the first commercial sale of a product, AT220,...

November 17, 2023 1 EN
 PRESS RELEASE
Free
AREC ARECOR THERAPEU...

Arecor: Business Update

Arecor: Business Update Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated during H2 and beyondSignificant progress across proprietary diabetes focused portfolio with AT278 scheduled to complete within Q4 2023Good partner progress across licensed portfolio Cambridge, UK, 20 July 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today provides a business update and annou...

July 20, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch